Pre-order Enquiry
Request Free Sample
Global Hydroxycarbamide Market Growth 2019-2024
SKU ID : LPI-13881557 | Publishing Date : 22-Feb-2019 | No. of pages : 164
Hydroxycarbamide, also known as hydroxyurea, is a medication used in sickle-cell disease, chronic myelogenous leukemia, cervical cancer, and polycythemia vera. In sickle-cell disease it decreases the number of attacks. It is taken by mouth.
Common side effects include bone marrow suppression, fevers, loss of appetite, psychiatric problems, shortness of breath, and headaches. There is also concern that it increases the risk of later cancers. Use during pregnancy is typically harmful to the baby. Hydroxycarbamide is in the antineoplastic family of medications. It is believed to work by blocking the making of DNA.
The classification of Hydroxycarbamide includes capsule and tablet, and the proportion of capsule in 2016 is about 63%, and the proportion is in decreasing trend from 2012 to 2016.
Hydroxycarbamide is widely used for sickle cell disease, cancer and other disease. The most proportion of Hydroxycarbamide is used for sickle cell disease, and the proportion in 2016 is 45%.
Asia Pacific is the largest supplier of Hydroxycarbamide, with a production market share nearly 59% in 2016.
Middle East and Africa is the largest consumption place, with a consumption market share nearly 36% in 2016. Following Middle East and Africa, Asia Pacific is the second largest consumption place with the consumption market share of 20%.
Market competition is not intense. Bristol Myers Squibb, Taj Pharma, Beijing Jialin Pharma, Qilu Pharmaceutical, Teva Pharma, Cipla, Zydus Cadila, United Biotech, Par Pharma, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
According to this study, over the next five years the Hydroxycarbamide market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Hydroxycarbamide business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Hydroxycarbamide market by product type, application, key manufacturers and key regions and countries.
This study considers the Hydroxycarbamide value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Capsule
Tablet
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Sickle Cell Disease
Cancer
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Bristol Myers Squibb
Taj Pharma
Beijing Jialin Pharma
Qilu Pharmaceutical
Teva Pharma
Cipla
Zydus Cadila
United Biotech
Par Pharma
Khandelwal Laboratories
Alkem (Cytomed)
Samarth Pharma
VHB Life Sciences
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Hydroxycarbamide consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Hydroxycarbamide market by identifying its various subsegments.
Focuses on the key global Hydroxycarbamide manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Hydroxycarbamide with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Hydroxycarbamide submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Common side effects include bone marrow suppression, fevers, loss of appetite, psychiatric problems, shortness of breath, and headaches. There is also concern that it increases the risk of later cancers. Use during pregnancy is typically harmful to the baby. Hydroxycarbamide is in the antineoplastic family of medications. It is believed to work by blocking the making of DNA.
The classification of Hydroxycarbamide includes capsule and tablet, and the proportion of capsule in 2016 is about 63%, and the proportion is in decreasing trend from 2012 to 2016.
Hydroxycarbamide is widely used for sickle cell disease, cancer and other disease. The most proportion of Hydroxycarbamide is used for sickle cell disease, and the proportion in 2016 is 45%.
Asia Pacific is the largest supplier of Hydroxycarbamide, with a production market share nearly 59% in 2016.
Middle East and Africa is the largest consumption place, with a consumption market share nearly 36% in 2016. Following Middle East and Africa, Asia Pacific is the second largest consumption place with the consumption market share of 20%.
Market competition is not intense. Bristol Myers Squibb, Taj Pharma, Beijing Jialin Pharma, Qilu Pharmaceutical, Teva Pharma, Cipla, Zydus Cadila, United Biotech, Par Pharma, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
According to this study, over the next five years the Hydroxycarbamide market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Hydroxycarbamide business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Hydroxycarbamide market by product type, application, key manufacturers and key regions and countries.
This study considers the Hydroxycarbamide value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Capsule
Tablet
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Sickle Cell Disease
Cancer
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Bristol Myers Squibb
Taj Pharma
Beijing Jialin Pharma
Qilu Pharmaceutical
Teva Pharma
Cipla
Zydus Cadila
United Biotech
Par Pharma
Khandelwal Laboratories
Alkem (Cytomed)
Samarth Pharma
VHB Life Sciences
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Hydroxycarbamide consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Hydroxycarbamide market by identifying its various subsegments.
Focuses on the key global Hydroxycarbamide manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Hydroxycarbamide with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Hydroxycarbamide submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Request Sample
Request Discount
